CDP 323
Alternative Names: CDP323Latest Information Update: 03 Jul 2009
At a glance
- Originator UCB
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Crohn's disease; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 30 Jun 2009 Discontinued - Phase-I for Multiple sclerosis in United Kingdom (PO)
- 30 Jun 2009 Discontinued - Phase-II for Multiple sclerosis in Belgium (PO)
- 30 Jun 2009 Discontinued - Phase-II for Multiple sclerosis in USA (PO)